Antiphospholipid antibodies and platelet activation as risk factors for thrombosis in thrombocythaemia

Carlos J. Bidot, Wenche Jy, Lawrence L. Horstman, Eugene R. Ahn, Loreta Bidot, Vincenzo Fontana, Yeon Ahn

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Risk factors for thrombosis (TB) in thrombocythaemia (TC) associated with myeloproliferative disorder (MPD) are not well defined. Methods: We measured antiphospholipid antibodies (APLA) in 35 patients with TC associated with MPD. Fourteen had TB and 21 did not. We assayed IgG and IgM APLA by ELISA for 6 antigens: β2GP1, cardiolipin (CL), phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylethanolamine (PE) and FVII/VIIa, together with markers of activation of platelets (CD62P) and endothelium [endothelial microparticles (EMP)]. Results: At least one positive APLA was detected in 66% of TC patients overall. The incidence was significantly higher in the TB subgroup (92.8%) than non-TB (47.6%, p < 0.05). Multiple APLA (positive for more than one antigen) were also more frequent in TB, for both IgG and IgM, for all 6 antigens tested (p < 0.05). However, IgM APLA predominated, being about 2-fold more frequently positive than IgG for all 6 antigens. Platelet CD62P was significantly higher in the TB group (p < 0.05). EMP did not differ between TB and non-TB. The most frequent thrombotic complication was recurring ischemic cerebral vascular accidents (ICVA), leading to progressive cognitive impairment. Venous TB often developed at unusual sites. Recurring and reversible TB were common features in TC. Summary: This study suggests that APLA and platelet activation are risk factors for TB in TC. APLA are prevalent in TC, and IgM APLA predominated over IgG. Activation of platelets but not of endothelium may be consistent with the reversible and recurrent features of TB in TC.

Original languageEnglish
Pages (from-to)451-456
Number of pages6
JournalHematology
Volume10
Issue number6
DOIs
StatePublished - Dec 1 2005

Fingerprint

Thrombocytosis
Antiphospholipid Antibodies
Platelet Activation
Thrombosis
Immunoglobulin M
Immunoglobulin G
Antigens
Myeloproliferative Disorders
Endothelium
Cardiolipins
Phosphatidylserines
Phosphatidylcholines
Venous Thrombosis
Accidents
Blood Vessels
Blood Platelets
Enzyme-Linked Immunosorbent Assay

Keywords

  • Antiphospholipid antibodies
  • Endothelial microparticles
  • Platelet activation
  • Thrombocythaemia
  • Thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Antiphospholipid antibodies and platelet activation as risk factors for thrombosis in thrombocythaemia. / Bidot, Carlos J.; Jy, Wenche; Horstman, Lawrence L.; Ahn, Eugene R.; Bidot, Loreta; Fontana, Vincenzo; Ahn, Yeon.

In: Hematology, Vol. 10, No. 6, 01.12.2005, p. 451-456.

Research output: Contribution to journalArticle

Bidot, Carlos J. ; Jy, Wenche ; Horstman, Lawrence L. ; Ahn, Eugene R. ; Bidot, Loreta ; Fontana, Vincenzo ; Ahn, Yeon. / Antiphospholipid antibodies and platelet activation as risk factors for thrombosis in thrombocythaemia. In: Hematology. 2005 ; Vol. 10, No. 6. pp. 451-456.
@article{2995b692e20a4ea9a6e9c771f6932c93,
title = "Antiphospholipid antibodies and platelet activation as risk factors for thrombosis in thrombocythaemia",
abstract = "Introduction: Risk factors for thrombosis (TB) in thrombocythaemia (TC) associated with myeloproliferative disorder (MPD) are not well defined. Methods: We measured antiphospholipid antibodies (APLA) in 35 patients with TC associated with MPD. Fourteen had TB and 21 did not. We assayed IgG and IgM APLA by ELISA for 6 antigens: β2GP1, cardiolipin (CL), phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylethanolamine (PE) and FVII/VIIa, together with markers of activation of platelets (CD62P) and endothelium [endothelial microparticles (EMP)]. Results: At least one positive APLA was detected in 66{\%} of TC patients overall. The incidence was significantly higher in the TB subgroup (92.8{\%}) than non-TB (47.6{\%}, p < 0.05). Multiple APLA (positive for more than one antigen) were also more frequent in TB, for both IgG and IgM, for all 6 antigens tested (p < 0.05). However, IgM APLA predominated, being about 2-fold more frequently positive than IgG for all 6 antigens. Platelet CD62P was significantly higher in the TB group (p < 0.05). EMP did not differ between TB and non-TB. The most frequent thrombotic complication was recurring ischemic cerebral vascular accidents (ICVA), leading to progressive cognitive impairment. Venous TB often developed at unusual sites. Recurring and reversible TB were common features in TC. Summary: This study suggests that APLA and platelet activation are risk factors for TB in TC. APLA are prevalent in TC, and IgM APLA predominated over IgG. Activation of platelets but not of endothelium may be consistent with the reversible and recurrent features of TB in TC.",
keywords = "Antiphospholipid antibodies, Endothelial microparticles, Platelet activation, Thrombocythaemia, Thrombosis",
author = "Bidot, {Carlos J.} and Wenche Jy and Horstman, {Lawrence L.} and Ahn, {Eugene R.} and Loreta Bidot and Vincenzo Fontana and Yeon Ahn",
year = "2005",
month = "12",
day = "1",
doi = "10.1080/10245330500226860",
language = "English",
volume = "10",
pages = "451--456",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Antiphospholipid antibodies and platelet activation as risk factors for thrombosis in thrombocythaemia

AU - Bidot, Carlos J.

AU - Jy, Wenche

AU - Horstman, Lawrence L.

AU - Ahn, Eugene R.

AU - Bidot, Loreta

AU - Fontana, Vincenzo

AU - Ahn, Yeon

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Introduction: Risk factors for thrombosis (TB) in thrombocythaemia (TC) associated with myeloproliferative disorder (MPD) are not well defined. Methods: We measured antiphospholipid antibodies (APLA) in 35 patients with TC associated with MPD. Fourteen had TB and 21 did not. We assayed IgG and IgM APLA by ELISA for 6 antigens: β2GP1, cardiolipin (CL), phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylethanolamine (PE) and FVII/VIIa, together with markers of activation of platelets (CD62P) and endothelium [endothelial microparticles (EMP)]. Results: At least one positive APLA was detected in 66% of TC patients overall. The incidence was significantly higher in the TB subgroup (92.8%) than non-TB (47.6%, p < 0.05). Multiple APLA (positive for more than one antigen) were also more frequent in TB, for both IgG and IgM, for all 6 antigens tested (p < 0.05). However, IgM APLA predominated, being about 2-fold more frequently positive than IgG for all 6 antigens. Platelet CD62P was significantly higher in the TB group (p < 0.05). EMP did not differ between TB and non-TB. The most frequent thrombotic complication was recurring ischemic cerebral vascular accidents (ICVA), leading to progressive cognitive impairment. Venous TB often developed at unusual sites. Recurring and reversible TB were common features in TC. Summary: This study suggests that APLA and platelet activation are risk factors for TB in TC. APLA are prevalent in TC, and IgM APLA predominated over IgG. Activation of platelets but not of endothelium may be consistent with the reversible and recurrent features of TB in TC.

AB - Introduction: Risk factors for thrombosis (TB) in thrombocythaemia (TC) associated with myeloproliferative disorder (MPD) are not well defined. Methods: We measured antiphospholipid antibodies (APLA) in 35 patients with TC associated with MPD. Fourteen had TB and 21 did not. We assayed IgG and IgM APLA by ELISA for 6 antigens: β2GP1, cardiolipin (CL), phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylethanolamine (PE) and FVII/VIIa, together with markers of activation of platelets (CD62P) and endothelium [endothelial microparticles (EMP)]. Results: At least one positive APLA was detected in 66% of TC patients overall. The incidence was significantly higher in the TB subgroup (92.8%) than non-TB (47.6%, p < 0.05). Multiple APLA (positive for more than one antigen) were also more frequent in TB, for both IgG and IgM, for all 6 antigens tested (p < 0.05). However, IgM APLA predominated, being about 2-fold more frequently positive than IgG for all 6 antigens. Platelet CD62P was significantly higher in the TB group (p < 0.05). EMP did not differ between TB and non-TB. The most frequent thrombotic complication was recurring ischemic cerebral vascular accidents (ICVA), leading to progressive cognitive impairment. Venous TB often developed at unusual sites. Recurring and reversible TB were common features in TC. Summary: This study suggests that APLA and platelet activation are risk factors for TB in TC. APLA are prevalent in TC, and IgM APLA predominated over IgG. Activation of platelets but not of endothelium may be consistent with the reversible and recurrent features of TB in TC.

KW - Antiphospholipid antibodies

KW - Endothelial microparticles

KW - Platelet activation

KW - Thrombocythaemia

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=31144433354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31144433354&partnerID=8YFLogxK

U2 - 10.1080/10245330500226860

DO - 10.1080/10245330500226860

M3 - Article

C2 - 16321809

AN - SCOPUS:31144433354

VL - 10

SP - 451

EP - 456

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 6

ER -